USA - NASDAQ:ATON - VGG7185A1369 - Common Stock
The current stock price of ATON is 6.25 USD.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.64 | 386.06B | ||
AMGN | AMGEN INC | 12.43 | 145.99B | ||
GILD | GILEAD SCIENCES INC | 14.34 | 137.72B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 97.91B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
REGN | REGENERON PHARMACEUTICALS | 12.17 | 58.88B | ||
ARGX | ARGENX SE - ADR | 76.71 | 43.52B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.75 | 39.08B | ||
INSM | INSMED INC | N/A | 28.66B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
NTRA | NATERA INC | N/A | 22.46B | ||
BIIB | BIOGEN INC | 8.47 | 19.89B |
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
ALPHATON CAPITAL CORP
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG
Employees: 3
Phone: 4167377600
The current stock price of ATON is 6.25 USD. The price increased by 3.82% in the last trading session.
The exchange symbol of ALPHATON CAPITAL CORP is ATON and it is listed on the Nasdaq exchange.
ATON stock is listed on the Nasdaq exchange.
ALPHATON CAPITAL CORP (ATON) has a market capitalization of 14.25M USD. This makes ATON a Nano Cap stock.
ALPHATON CAPITAL CORP (ATON) currently has 3 employees.
ALPHATON CAPITAL CORP (ATON) has a support level at 6.01. Check the full technical report for a detailed analysis of ATON support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ATON does not pay a dividend.
ALPHATON CAPITAL CORP (ATON) will report earnings on 2025-11-24.
ALPHATON CAPITAL CORP (ATON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.72).
ChartMill assigns a technical rating of 3 / 10 to ATON.
ChartMill assigns a fundamental rating of 1 / 10 to ATON. ATON may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ATON reported a non-GAAP Earnings per Share(EPS) of -5.72. The EPS increased by 92.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -304.13% | ||
ROE | N/A | ||
Debt/Equity | N/A |